The Revimmune paper I read states "The principal investigator for the
ongoing Revimmune MS study at the Johns Hopkins University School of Medicine is Douglas Kerr, MD, PhD. In a follow-up of up to 2 years, most patients have shown substantial improvement and many have a complete elimination of signs of the disease."
It also states "Accentia is preparing an IND application for Revimmune for severe refractory MS, and is proposing to enter a Phase III clinical trial to support licensure under the abbreviated 505(b)(2) regulatory pathway"
I used the word clinical trial without realizing the difference between a study and a clinical trial. Is it a "study" that John Hopkins is currently conducting.